drugset
drugset / Trial / NCT00529100

Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer

NCT00529100 ↗

Phase 1/2 Completed 49 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Measure the 1 year survival of non small cell lung cancer (NSCLC) patients who are being treated with pemetrexed in combination with cisplatin and radiation.

Timeline

Start
2005-12
Primary completion
2010-08
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 20 mg/m2 Intravenous
Subject Cisplatin Other / unclassified 25 mg/m2 Intravenous
Subject Pemetrexed Small molecule 300 mg/m2 Intravenous
Subject Pemetrexed Small molecule 400 mg/m2 Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

non-small cell lung carcinoma